TENOSYNOVIAL GIANT CELL TUMOR, DIFFUSE
Clinical trials for TENOSYNOVIAL GIANT CELL TUMOR, DIFFUSE explained in plain language.
Never miss a new study
Get alerted when new TENOSYNOVIAL GIANT CELL TUMOR, DIFFUSE trials appear
Sign up with your email to follow new studies for TENOSYNOVIAL GIANT CELL TUMOR, DIFFUSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill could shrink rare joint tumors without surgery
Disease control OngoingThis phase 3 trial tests vimseltinib, an oral drug, for tenosynovial giant cell tumor (TGCT) when surgery isn't possible. About 123 adults with symptomatic TGCT will receive either vimseltinib or a placebo for 24 weeks, then all can get the drug. The main goal is to see if the dr…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR, DIFFUSE
Phase: PHASE3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
New drug shows promise for rare joint tumor and advanced cancers
Disease control OngoingThis study tests an experimental drug called vimseltinib in people with advanced solid tumors or a rare joint tumor called tenosynovial giant cell tumor (TGCT). The goal is to find the safest dose and see if the drug shrinks tumors. About 120 adults will take part in two phases: …
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR, DIFFUSE
Phase: PHASE1, PHASE2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 18, 2026 11:46 UTC